R&D channel feed

FDA ad­comm votes nar­row­ly against Veru's Covid drug, cit­ing un­cer­tain­ties amid mor­tal­i­ty ben­e­fit in small tri­al

3 years ago
FDA+

Ipsen claims pos­i­tive PhI­II in drug once owned by Mer­ri­mack, whose shares jump pend­ing pos­si­ble nine-fig­ure pay­out

3 years ago

No­vavax tem­pers its rev­enue ex­pec­ta­tions as it un­veils PhI­II da­ta for bi­va­lent boost­er

3 years ago
Pharma
Coronavirus

Up­dat­ed: Two years af­ter launch, Third Rock-backed neu­ro start­up Faze Med­i­cines is clos­ing its doors — re­port

3 years ago
Startups

FDA ad­comm of­fers thumbs up on As­traZeneca's 2-in-1 asth­ma in­haler — but on­ly for adults

3 years ago
FDA+

Not a home run, but first base: GSK un­wraps PhII da­ta on he­pati­tis B treat­ment in pur­suit of ‘func­tion­al cure’

3 years ago

Nor­bert Bischof­berg­er ices a PhI­II AML drug — for the sec­ond time in his ca­reer

3 years ago

Am­gen may be way late to the obe­si­ty game, but the mar­ket scouts are lov­ing the block­buster po­ten­tial of AMG 133

3 years ago
Bioregnum

Start­ing with ADC, FDA calls for ful­ly en­rolled con­fir­ma­to­ry tri­al pri­or to ac­cel­er­at­ed ap­proval sub­mis­sion

3 years ago

While PhI­II Parkin­son's tri­als go slow­er than ex­pect­ed, Cerev­el pre­views plans to raise $900M

3 years ago
Financing

J&J, Idor­sia build out piv­otal dataset for their $230M hy­per­ten­sion drug, show­ing a main­tained re­sponse

3 years ago

In lat­est AI tie-up, Sanofi part­ners with In­sil­i­co for six new tar­gets

3 years ago
Deals
AI

Al­tos Labs founders Bar­ron and Klaus­ner: 'There are mech­a­nisms in the cell where you can re­set not the stress curve, but the re­silience curve'

3 years ago

Two for­mer Stan­ford re­searchers nab a $41M launch round to learn the se­crets of the ‘se­cre­tome’

3 years ago
Startups
AI

With all hands on deck for lead sick­le cell tri­al, Beam pulls back clin­i­cal plans for sec­ond base edit­ing ther­a­py

3 years ago
Cell/Gene Tx

As Roche pre­pares to take a kid­ney dis­ease drug in­to PhI­II, Io­n­is flesh­es out the da­ta

3 years ago

Up­dat­ed: Verve's land­mark base edit­ing tri­al for car­dio drug runs in­to FDA hold

3 years ago
Cell/Gene Tx
FDA+

GSK re­ports PhI­II flop for BC­MA drug — rais­ing ques­tions about its fu­ture and up­ping the stakes on com­bos

3 years ago

Am­gen maps a PhI­II jour­ney for its lat­est great car­dio drug hope­ful. Can it suc­ceed this time?

3 years ago

FDA de­lays de­ci­sion for Apel­lis' eye dis­ease drug af­ter biotech sub­mits up­dat­ed da­ta

3 years ago
FDA+

Three years af­ter un­der­whelm­ing da­ta, Lieping Chen's NextCure drops lead pro­gram

3 years ago

Bay­er drops an Io­n­is-part­nered drug af­ter sink­ing $240M in­to its de­vel­op­ment

3 years ago
Deals

Up­dat­ed: Cit­ing ef­fi­ca­cy, GSK halts UTI an­tibi­ot­ic tri­al ear­ly, plans to file for FDA ap­proval next year

3 years ago

Small start­up touts a PhI­II suc­cess in rare 'but­ter­fly skin' dis­ease af­ter an FDA hold rout­ed shares

3 years ago
First page Previous page 111112113114115116117 Next page Last page
A service from the Financial Times